Alicia Katherine Morgans, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 91 | 2024 | 11057 | 7.710 |
Why?
|
Androgen Antagonists | 35 | 2024 | 1400 | 5.520 |
Why?
|
Quality of Life | 26 | 2024 | 13263 | 1.560 |
Why?
|
Urogenital Neoplasms | 3 | 2020 | 129 | 1.420 |
Why?
|
Nitriles | 7 | 2024 | 950 | 1.400 |
Why?
|
Carcinoma, Transitional Cell | 4 | 2024 | 772 | 1.280 |
Why?
|
Phenylthiohydantoin | 5 | 2024 | 199 | 1.270 |
Why?
|
Urinary Bladder Neoplasms | 6 | 2024 | 2195 | 1.260 |
Why?
|
Neoplasm Metastasis | 13 | 2024 | 4886 | 1.110 |
Why?
|
Prostate-Specific Antigen | 12 | 2024 | 2456 | 0.980 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 19 | 2024 | 11709 | 0.950 |
Why?
|
Benzamides | 5 | 2024 | 1363 | 0.950 |
Why?
|
Male | 125 | 2024 | 358180 | 0.880 |
Why?
|
Drug Interactions | 2 | 2024 | 1415 | 0.790 |
Why?
|
Hot Flashes | 1 | 2023 | 328 | 0.730 |
Why?
|
Androgen Receptor Antagonists | 4 | 2024 | 121 | 0.690 |
Why?
|
Medical Oncology | 8 | 2023 | 2308 | 0.680 |
Why?
|
Prostatectomy | 8 | 2024 | 1821 | 0.680 |
Why?
|
Urologic Neoplasms | 1 | 2023 | 310 | 0.660 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2019 | 48 | 0.650 |
Why?
|
Humans | 143 | 2024 | 757566 | 0.640 |
Why?
|
Clinical Trials as Topic | 6 | 2024 | 7982 | 0.640 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2018 | 37 | 0.620 |
Why?
|
Bone Density | 6 | 2023 | 3530 | 0.610 |
Why?
|
Receptors, Androgen | 7 | 2024 | 1073 | 0.600 |
Why?
|
Antineoplastic Agents | 9 | 2024 | 13597 | 0.590 |
Why?
|
Hormones | 7 | 2023 | 867 | 0.570 |
Why?
|
Decision Making | 5 | 2023 | 3909 | 0.560 |
Why?
|
Cisplatin | 3 | 2023 | 1647 | 0.530 |
Why?
|
Germ-Line Mutation | 5 | 2023 | 1841 | 0.520 |
Why?
|
Toremifene | 2 | 2012 | 24 | 0.500 |
Why?
|
Antineoplastic Agents, Hormonal | 5 | 2023 | 1516 | 0.500 |
Why?
|
Cardiovascular Diseases | 9 | 2024 | 15398 | 0.500 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 490 | 0.490 |
Why?
|
Drug Therapy | 1 | 2018 | 503 | 0.480 |
Why?
|
Osteoporosis | 3 | 2020 | 1598 | 0.480 |
Why?
|
Urinary Incontinence | 5 | 2024 | 489 | 0.470 |
Why?
|
Metformin | 1 | 2022 | 905 | 0.460 |
Why?
|
Molecular Targeted Therapy | 4 | 2022 | 2796 | 0.440 |
Why?
|
Aged | 38 | 2024 | 167890 | 0.430 |
Why?
|
Feasibility Studies | 1 | 2023 | 5194 | 0.420 |
Why?
|
Neoplasms | 10 | 2024 | 21986 | 0.420 |
Why?
|
Androgens | 5 | 2024 | 1281 | 0.410 |
Why?
|
Central Nervous System | 1 | 2019 | 1332 | 0.410 |
Why?
|
Fractures, Bone | 3 | 2023 | 2039 | 0.390 |
Why?
|
Treatment Outcome | 24 | 2023 | 64242 | 0.390 |
Why?
|
Survivors | 9 | 2024 | 2370 | 0.380 |
Why?
|
Taxoids | 2 | 2024 | 666 | 0.340 |
Why?
|
Motivation | 1 | 2019 | 1996 | 0.340 |
Why?
|
Hypertension, Renal | 1 | 2009 | 135 | 0.340 |
Why?
|
Cognition | 4 | 2022 | 6952 | 0.330 |
Why?
|
Prostate | 8 | 2024 | 1757 | 0.310 |
Why?
|
Gonadotropin-Releasing Hormone | 3 | 2024 | 1146 | 0.300 |
Why?
|
Cognition Disorders | 1 | 2022 | 3975 | 0.300 |
Why?
|
Early Detection of Cancer | 4 | 2022 | 3164 | 0.300 |
Why?
|
Bone Neoplasms | 4 | 2022 | 2524 | 0.300 |
Why?
|
Diabetes Complications | 1 | 2014 | 1317 | 0.290 |
Why?
|
Combined Modality Therapy | 6 | 2019 | 8512 | 0.290 |
Why?
|
Piperazines | 3 | 2024 | 2511 | 0.290 |
Why?
|
Depression | 3 | 2020 | 8049 | 0.280 |
Why?
|
Neoplasm Staging | 10 | 2022 | 11082 | 0.280 |
Why?
|
Palliative Care | 2 | 2019 | 3568 | 0.280 |
Why?
|
Erectile Dysfunction | 3 | 2015 | 444 | 0.280 |
Why?
|
Lymphoproliferative Disorders | 1 | 2009 | 533 | 0.260 |
Why?
|
United States | 20 | 2024 | 71902 | 0.260 |
Why?
|
Dementia | 1 | 2020 | 2649 | 0.260 |
Why?
|
Urology | 2 | 2020 | 400 | 0.250 |
Why?
|
Adenocarcinoma | 3 | 2018 | 6323 | 0.240 |
Why?
|
Disease Management | 5 | 2019 | 2495 | 0.240 |
Why?
|
Thiohydantoins | 1 | 2024 | 18 | 0.240 |
Why?
|
Referral and Consultation | 3 | 2019 | 3579 | 0.240 |
Why?
|
Bone Density Conservation Agents | 1 | 2012 | 792 | 0.230 |
Why?
|
Hospitalization | 1 | 2024 | 10634 | 0.230 |
Why?
|
Genetic Testing | 4 | 2021 | 3529 | 0.230 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2024 | 80 | 0.230 |
Why?
|
Pyrimidinones | 2 | 2023 | 383 | 0.220 |
Why?
|
Bone and Bones | 1 | 2014 | 2558 | 0.220 |
Why?
|
Immunotherapy | 3 | 2018 | 4641 | 0.220 |
Why?
|
Phenylurea Compounds | 2 | 2023 | 527 | 0.210 |
Why?
|
Cardiovascular System | 2 | 2021 | 835 | 0.210 |
Why?
|
Watchful Waiting | 3 | 2024 | 492 | 0.210 |
Why?
|
Disease-Free Survival | 4 | 2022 | 6807 | 0.210 |
Why?
|
Orchiectomy | 3 | 2020 | 463 | 0.210 |
Why?
|
Radiotherapy | 3 | 2024 | 1498 | 0.210 |
Why?
|
Budgets | 1 | 2024 | 229 | 0.210 |
Why?
|
Risk Assessment | 8 | 2023 | 23816 | 0.210 |
Why?
|
Continuity of Patient Care | 2 | 2020 | 1067 | 0.200 |
Why?
|
Phthalazines | 2 | 2024 | 382 | 0.200 |
Why?
|
5-Methylcytosine | 1 | 2022 | 146 | 0.200 |
Why?
|
Middle Aged | 24 | 2024 | 219192 | 0.200 |
Why?
|
Prednisone | 4 | 2023 | 1563 | 0.200 |
Why?
|
Leuprolide | 1 | 2023 | 310 | 0.200 |
Why?
|
Internal-External Control | 1 | 2023 | 359 | 0.190 |
Why?
|
Androstenes | 2 | 2021 | 180 | 0.190 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2020 | 1788 | 0.170 |
Why?
|
Antigens, Surface | 1 | 2024 | 1607 | 0.170 |
Why?
|
Lutetium | 3 | 2024 | 34 | 0.170 |
Why?
|
Aged, 80 and over | 12 | 2024 | 58558 | 0.170 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17767 | 0.170 |
Why?
|
Genomics | 3 | 2021 | 5788 | 0.160 |
Why?
|
Heterocyclic Compounds, 1-Ring | 3 | 2024 | 65 | 0.160 |
Why?
|
Quality Indicators, Health Care | 2 | 2022 | 1791 | 0.160 |
Why?
|
Prognosis | 11 | 2024 | 29488 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2020 | 3510 | 0.160 |
Why?
|
Patient Selection | 3 | 2023 | 4235 | 0.160 |
Why?
|
Consensus | 4 | 2022 | 3097 | 0.150 |
Why?
|
Personal Satisfaction | 1 | 2023 | 641 | 0.150 |
Why?
|
Survival Rate | 5 | 2024 | 12684 | 0.150 |
Why?
|
Diabetes Mellitus | 3 | 2016 | 5815 | 0.150 |
Why?
|
Genes, BRCA2 | 1 | 2021 | 603 | 0.150 |
Why?
|
Genes, BRCA1 | 1 | 2021 | 765 | 0.140 |
Why?
|
Dipeptides | 3 | 2024 | 386 | 0.140 |
Why?
|
Retinoblastoma Protein | 1 | 2021 | 670 | 0.140 |
Why?
|
SEER Program | 3 | 2024 | 1454 | 0.140 |
Why?
|
Pyrazoles | 2 | 2024 | 1992 | 0.140 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 7366 | 0.140 |
Why?
|
Delphi Technique | 2 | 2022 | 828 | 0.140 |
Why?
|
Vascular Neoplasms | 1 | 2018 | 166 | 0.140 |
Why?
|
Gonadal Steroid Hormones | 1 | 2020 | 701 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2024 | 949 | 0.130 |
Why?
|
Risk Factors | 11 | 2024 | 73708 | 0.130 |
Why?
|
Osteoporotic Fractures | 1 | 2020 | 408 | 0.130 |
Why?
|
Uterine Artery Embolization | 1 | 2016 | 59 | 0.130 |
Why?
|
Carboplatin | 1 | 2018 | 792 | 0.130 |
Why?
|
Balloon Occlusion | 1 | 2016 | 125 | 0.120 |
Why?
|
Prospective Studies | 9 | 2024 | 54092 | 0.120 |
Why?
|
Meta-Analysis as Topic | 1 | 2019 | 1373 | 0.120 |
Why?
|
Research | 1 | 2023 | 1974 | 0.120 |
Why?
|
Kidney Transplantation | 1 | 2009 | 4214 | 0.120 |
Why?
|
Radiopharmaceuticals | 1 | 2024 | 2634 | 0.120 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2024 | 850 | 0.110 |
Why?
|
Comprehension | 1 | 2019 | 618 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2022 | 2318 | 0.110 |
Why?
|
Retrospective Studies | 9 | 2024 | 79984 | 0.110 |
Why?
|
Hormone Replacement Therapy | 1 | 2019 | 748 | 0.110 |
Why?
|
Samarium | 1 | 2012 | 3 | 0.110 |
Why?
|
Indoles | 1 | 2021 | 1824 | 0.110 |
Why?
|
Life Expectancy | 1 | 2019 | 1238 | 0.100 |
Why?
|
Drug Approval | 1 | 2020 | 808 | 0.100 |
Why?
|
Clodronic Acid | 1 | 2012 | 59 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3077 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3197 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1087 | 0.100 |
Why?
|
Radioisotopes | 2 | 2024 | 495 | 0.100 |
Why?
|
Cost-Benefit Analysis | 2 | 2022 | 5483 | 0.100 |
Why?
|
Postpartum Hemorrhage | 1 | 2016 | 265 | 0.100 |
Why?
|
Absorptiometry, Photon | 2 | 2023 | 1735 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2023 | 10135 | 0.100 |
Why?
|
DNA Repair | 1 | 2021 | 2038 | 0.100 |
Why?
|
Testicular Neoplasms | 1 | 2018 | 794 | 0.100 |
Why?
|
Kidney Neoplasms | 2 | 2021 | 4220 | 0.100 |
Why?
|
Comparative Effectiveness Research | 2 | 2014 | 707 | 0.100 |
Why?
|
Patient Care Team | 1 | 2022 | 2505 | 0.090 |
Why?
|
DNA Damage | 1 | 2021 | 2439 | 0.090 |
Why?
|
Molecular Imaging | 1 | 2018 | 813 | 0.090 |
Why?
|
Truth Disclosure | 1 | 2015 | 433 | 0.090 |
Why?
|
Cohort Studies | 6 | 2023 | 41190 | 0.090 |
Why?
|
Fractures, Spontaneous | 1 | 2012 | 231 | 0.090 |
Why?
|
Intensive Care Units | 1 | 2024 | 3732 | 0.090 |
Why?
|
Time Factors | 5 | 2020 | 39811 | 0.090 |
Why?
|
Self Report | 2 | 2019 | 3709 | 0.090 |
Why?
|
Colonic Neoplasms | 1 | 2022 | 2522 | 0.090 |
Why?
|
Incidence | 5 | 2019 | 21217 | 0.090 |
Why?
|
Hip | 1 | 2012 | 251 | 0.090 |
Why?
|
Proportional Hazards Models | 2 | 2023 | 12397 | 0.090 |
Why?
|
Length of Stay | 1 | 2024 | 6384 | 0.090 |
Why?
|
Patient Satisfaction | 1 | 2023 | 3440 | 0.090 |
Why?
|
Double-Blind Method | 1 | 2024 | 12261 | 0.090 |
Why?
|
Nephrectomy | 1 | 2015 | 934 | 0.090 |
Why?
|
Gene Deletion | 1 | 2017 | 2666 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2306 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2024 | 39020 | 0.080 |
Why?
|
Intestinal Diseases | 1 | 2014 | 504 | 0.080 |
Why?
|
Platelet Adhesiveness | 1 | 2009 | 153 | 0.080 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1402 | 0.080 |
Why?
|
Intercellular Junctions | 1 | 2009 | 195 | 0.080 |
Why?
|
Pain | 3 | 2023 | 5063 | 0.080 |
Why?
|
Pyridines | 1 | 2021 | 2864 | 0.080 |
Why?
|
Valsalva Maneuver | 1 | 2009 | 99 | 0.080 |
Why?
|
Databases, Factual | 2 | 2021 | 7927 | 0.080 |
Why?
|
International Cooperation | 1 | 2015 | 1428 | 0.080 |
Why?
|
Lymph Nodes | 2 | 2018 | 3470 | 0.080 |
Why?
|
Osteoclasts | 1 | 2012 | 710 | 0.080 |
Why?
|
Data Collection | 2 | 2014 | 3319 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2018 | 1991 | 0.070 |
Why?
|
Models, Biological | 1 | 2024 | 9459 | 0.070 |
Why?
|
Pain Measurement | 1 | 2018 | 3523 | 0.070 |
Why?
|
Ablation Techniques | 2 | 2020 | 247 | 0.070 |
Why?
|
Diphosphonates | 1 | 2012 | 636 | 0.070 |
Why?
|
Affect | 1 | 2015 | 1480 | 0.070 |
Why?
|
Placebos | 1 | 2012 | 1661 | 0.070 |
Why?
|
Societies, Medical | 4 | 2020 | 3887 | 0.070 |
Why?
|
Complementary Therapies | 1 | 2011 | 486 | 0.070 |
Why?
|
Pancreatectomy | 1 | 2011 | 808 | 0.070 |
Why?
|
Health Status | 1 | 2019 | 4066 | 0.070 |
Why?
|
Pandemics | 3 | 2022 | 8600 | 0.070 |
Why?
|
Tachycardia | 1 | 2009 | 600 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2024 | 5325 | 0.070 |
Why?
|
Imidazoles | 1 | 2012 | 1178 | 0.070 |
Why?
|
Urinary Bladder | 2 | 2023 | 1148 | 0.060 |
Why?
|
Recurrence | 1 | 2018 | 8426 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2023 | 9245 | 0.060 |
Why?
|
Femur | 1 | 2012 | 1301 | 0.060 |
Why?
|
Age Factors | 4 | 2015 | 18326 | 0.060 |
Why?
|
Platelet Activation | 2 | 2009 | 645 | 0.060 |
Why?
|
Spine | 1 | 2012 | 1111 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2023 | 20992 | 0.060 |
Why?
|
Adult | 10 | 2024 | 219725 | 0.060 |
Why?
|
Body Mass Index | 1 | 2022 | 12868 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5253 | 0.060 |
Why?
|
Heart Neoplasms | 1 | 2007 | 360 | 0.060 |
Why?
|
Odds Ratio | 2 | 2015 | 9624 | 0.060 |
Why?
|
Biomedical Research | 1 | 2019 | 3415 | 0.060 |
Why?
|
Health Promotion | 1 | 2015 | 2201 | 0.050 |
Why?
|
Heart | 1 | 2016 | 4382 | 0.050 |
Why?
|
Health Status Disparities | 1 | 2015 | 1821 | 0.050 |
Why?
|
Cell Adhesion Molecules | 1 | 2009 | 1600 | 0.050 |
Why?
|
Medicare | 1 | 2021 | 6724 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3013 | 0.050 |
Why?
|
Injections, Intramuscular | 1 | 2024 | 553 | 0.050 |
Why?
|
Salivary Glands | 1 | 2024 | 229 | 0.050 |
Why?
|
Injections, Subcutaneous | 1 | 2024 | 678 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 8981 | 0.050 |
Why?
|
Risk | 1 | 2014 | 9590 | 0.050 |
Why?
|
Indazoles | 1 | 2024 | 302 | 0.050 |
Why?
|
Testosterone | 2 | 2023 | 2465 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 2 | 2023 | 20499 | 0.050 |
Why?
|
Diagnostic Imaging | 2 | 2023 | 3524 | 0.050 |
Why?
|
Kidney | 1 | 2016 | 7012 | 0.050 |
Why?
|
Communication | 1 | 2015 | 3841 | 0.050 |
Why?
|
Liver | 1 | 2016 | 7502 | 0.050 |
Why?
|
Disease Progression | 1 | 2017 | 13463 | 0.040 |
Why?
|
Platelet Aggregation | 1 | 2004 | 773 | 0.040 |
Why?
|
Therapies, Investigational | 1 | 2021 | 111 | 0.040 |
Why?
|
Nomograms | 1 | 2022 | 227 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2015 | 3152 | 0.040 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9163 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2015 | 3317 | 0.040 |
Why?
|
San Francisco | 1 | 2019 | 162 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 199 | 0.040 |
Why?
|
Blood Pressure | 2 | 2016 | 8453 | 0.040 |
Why?
|
Oligopeptides | 1 | 2024 | 1184 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5648 | 0.040 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3670 | 0.040 |
Why?
|
Female | 11 | 2023 | 389943 | 0.040 |
Why?
|
Comorbidity | 3 | 2020 | 10477 | 0.040 |
Why?
|
Hypogonadism | 1 | 2024 | 798 | 0.040 |
Why?
|
Blood Coagulation | 1 | 2004 | 1150 | 0.040 |
Why?
|
Thrombosis | 2 | 2009 | 2931 | 0.040 |
Why?
|
Markov Chains | 1 | 2021 | 965 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2007 | 1402 | 0.040 |
Why?
|
Organizational Innovation | 1 | 2020 | 536 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2009 | 1915 | 0.040 |
Why?
|
Bleomycin | 1 | 2018 | 494 | 0.040 |
Why?
|
Etoposide | 1 | 2018 | 634 | 0.030 |
Why?
|
Kallikreins | 1 | 2018 | 218 | 0.030 |
Why?
|
Germ Cells | 1 | 2020 | 634 | 0.030 |
Why?
|
American Heart Association | 1 | 2021 | 1039 | 0.030 |
Why?
|
Melanoma | 1 | 2015 | 5689 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 426 | 0.030 |
Why?
|
Heart Function Tests | 1 | 2016 | 318 | 0.030 |
Why?
|
Signal Transduction | 3 | 2024 | 23335 | 0.030 |
Why?
|
Piperidines | 1 | 2024 | 1639 | 0.030 |
Why?
|
Advisory Committees | 1 | 2019 | 780 | 0.030 |
Why?
|
Genetic Counseling | 1 | 2019 | 624 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2016 | 522 | 0.030 |
Why?
|
Preventive Health Services | 1 | 2019 | 567 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 676 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12951 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2021 | 940 | 0.030 |
Why?
|
Pituitary Diseases | 1 | 2015 | 135 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 842 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2011 | 5348 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2019 | 826 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2020 | 1263 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2023 | 14473 | 0.030 |
Why?
|
Blood Platelets | 1 | 2004 | 2476 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2015 | 410 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 1 | 2022 | 2047 | 0.030 |
Why?
|
Prevalence | 2 | 2023 | 15640 | 0.030 |
Why?
|
History, 20th Century | 1 | 2020 | 2769 | 0.020 |
Why?
|
Soft Tissue Neoplasms | 1 | 2021 | 1152 | 0.020 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2008 | 3599 | 0.020 |
Why?
|
Uterus | 1 | 2016 | 649 | 0.020 |
Why?
|
Remission Induction | 2 | 2008 | 2390 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2024 | 10749 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2021 | 2859 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2004 | 4492 | 0.020 |
Why?
|
Pruritus | 1 | 2015 | 377 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 25924 | 0.020 |
Why?
|
Biopsy | 1 | 2022 | 6757 | 0.020 |
Why?
|
Health Expenditures | 1 | 2023 | 2342 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2913 | 0.020 |
Why?
|
Exanthema | 1 | 2015 | 505 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2017 | 1533 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3591 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2278 | 0.020 |
Why?
|
Cause of Death | 1 | 2020 | 3667 | 0.020 |
Why?
|
Age Distribution | 1 | 2015 | 2877 | 0.020 |
Why?
|
Exercise | 2 | 2016 | 5788 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 2809 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2015 | 1787 | 0.020 |
Why?
|
Hypercholesterolemia | 1 | 2015 | 1141 | 0.020 |
Why?
|
Neuralgia | 1 | 2015 | 600 | 0.020 |
Why?
|
Diarrhea | 1 | 2015 | 1317 | 0.020 |
Why?
|
Medical Records | 1 | 2013 | 1406 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3055 | 0.020 |
Why?
|
Registries | 1 | 2023 | 8164 | 0.020 |
Why?
|
Sleep | 1 | 2022 | 4745 | 0.020 |
Why?
|
Hemostasis | 1 | 2009 | 466 | 0.020 |
Why?
|
Cholesterol | 1 | 2016 | 2901 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3762 | 0.020 |
Why?
|
Mass Screening | 1 | 2022 | 5412 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 4710 | 0.020 |
Why?
|
Colitis | 1 | 2015 | 1229 | 0.020 |
Why?
|
Mental Health | 1 | 2020 | 3228 | 0.020 |
Why?
|
Pressure | 1 | 2009 | 1154 | 0.020 |
Why?
|
Vincristine | 1 | 2007 | 1036 | 0.020 |
Why?
|
Regression Analysis | 1 | 2014 | 6337 | 0.020 |
Why?
|
Posture | 1 | 2009 | 954 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 693 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6470 | 0.010 |
Why?
|
Bleeding Time | 1 | 2004 | 83 | 0.010 |
Why?
|
Patient Participation | 1 | 2013 | 1435 | 0.010 |
Why?
|
Aspirin | 1 | 2016 | 3128 | 0.010 |
Why?
|
Phenotype | 1 | 2022 | 16533 | 0.010 |
Why?
|
Life Style | 1 | 2015 | 3886 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2015 | 2045 | 0.010 |
Why?
|
Linear Models | 1 | 2014 | 5856 | 0.010 |
Why?
|
Protein Transport | 1 | 2009 | 1963 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2011 | 2914 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2007 | 2219 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10495 | 0.010 |
Why?
|
Doxorubicin | 1 | 2007 | 2211 | 0.010 |
Why?
|
Fibrinogen | 1 | 2004 | 883 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13221 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2004 | 1694 | 0.010 |
Why?
|
Survival Analysis | 1 | 2011 | 10075 | 0.010 |
Why?
|
Diet | 1 | 2015 | 8001 | 0.010 |
Why?
|
Lung Diseases | 1 | 2007 | 1908 | 0.010 |
Why?
|
Antigens, CD | 1 | 2007 | 3996 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 29929 | 0.010 |
Why?
|
Child | 1 | 2024 | 79782 | 0.010 |
Why?
|
Hypertension | 1 | 2015 | 8502 | 0.010 |
Why?
|
Adolescent | 1 | 2024 | 87819 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2004 | 2443 | 0.010 |
Why?
|
Echocardiography | 1 | 2007 | 4963 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2008 | 3752 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2009 | 14345 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 29712 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2007 | 6457 | 0.010 |
Why?
|
Mice | 2 | 2009 | 81066 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2004 | 12761 | 0.000 |
Why?
|
Young Adult | 1 | 2015 | 58755 | 0.000 |
Why?
|
Animals | 2 | 2009 | 167718 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2007 | 36270 | 0.000 |
Why?
|